Show simple item record

dc.contributor.authorLamorde, Mohammed
dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorMerry, Concepta
dc.date.accessioned2011-12-29T12:21:56Z
dc.date.available2011-12-29T12:21:56Z
dc.date.issued2008
dc.identifier.citationLamorde M,Byakika-Kibwika P,Merry C. Antiretroviral therapy in developing countries: pharmacologic considerations Vol 3en_US
dc.identifier.issn1746-630X
dc.identifier.urihttp://hdl.handle.net/10570/273
dc.description.abstractPurpose of review This article reviews recent studies in the field of clinical pharmacology of antiretroviral drugs and highlights the relevance of the findings to clinical practice in developing countries. Recent findings Differences in antiretroviral pharmacokinetics are associated with polymorphisms of genes encoding drug metabolizing enzymes. Inadequate concentrations of antiretrovirals in children are common. A study in African children found subtherapeutic concentrations in 40% of patients receiving efavirenz at recommended doses. Summary Recent findings on the pharmacokinetics of antiretroviral agents relevant to clinical practice in developing countries are reviewed. Widespread poverty impacts negatively on HIV/AIDS treatment and prevention efforts. Improved access to treatment, social and economic support and pharmacology research in target populations are needed.en_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.subjectAnti-HIV agentsen_US
dc.subjectDeveloping countriesen_US
dc.subjectDrug interactionsen_US
dc.subjectPharmacokineticsen_US
dc.subjectToxicityen_US
dc.titleAntiretroviral therapy in developing countries: pharmacologic considerationsen_US
dc.typeJournal article, peer revieweden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record